Genetic Cardiomyopathies Market Share

North American Market Forecast

The genetic cardiomyopathies market in North America is projected to be the largest with a share of about 38% by the end of 2036. The growth of the market can be attributed majorly to the rising investment in the research and development of gene therapies. Overall private equity and venture capital investment has increased in North America, with a compound annual growth rate of 18% for life sciences from 2010 to 2021. Over the same period, the average growth rate for gene therapy was 59%. Cell treatment has expanded by 63%. This indicates an increase in investment from around USD 360 million in 2020 to over nearly 70 billion in 2021.

APAC Market Statistics

The Asia Pacific genetic cardiomyopathies market is estimated to be the second largest, registering a share of about 25% by the end of 2036. The growth of the market can be attributed majorly to the growing levels of pollution in the atmosphere in the region. Air pollution has been linked to negative cardiac remodelling in patients with dilated cardiomyopathy. Women appear to be more vulnerable to these impacts. Almost 90% of the Asia-Pacific region's population habitually breathes air deemed unhealthy by the World Health Organization (WHO). Air pollution is responsible for more than 7 million premature deaths worldwide, with the Asia-Pacific area accounting for two-thirds of those mortality.